Clinical trials: ALK
ALK-POSITIVE NSCLC
The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] Ensartinib in healthy Chinese male subjects.
- Trial name
- NCT03804541
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
ALK-Positive Anaplastic Large Cell Lymphoma
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients with relapsed and refractory…
- Trial name
- NCT03707847
- Testing
- Crizotinib, Etoposide Capsule, Auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental arm) with CHOP (control arm) in previously untreated T-cell lymphoma.
- Conditions
- Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic Gamma/ Delta T-cell Lymphoma
- Trial name
- CHEMO-T (NCT01719835)
- Testing
- Cyclophosphamide, Gemcitabine, Doxorubicin
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- Royal Marsden NHS Foundation Trust
ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
T cell lymphoma is a heterogenic malignancy with poor outcome. Five-year PFS and OS of the patients recieved classic CHOP regimen(cyclophosphamide,vincristin,doxorubicin and predisone)is less than 30%.High dose intensive…
- Conditions
- ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, Enteropathy Associated T Cell Lymphoma
- Trial name
- NCT01746992
- Testing
- Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
The urgent need for new effective therapy for T-cell lymphoma patients and promising results observed so far in trials with RAD001(everolimus, mTOR inhibitor) strongly warrants the investigation of RAD001 combined with CHOP as a…
- Conditions
- Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T Cell Lymphoma, Cutaneous T Cell Lymphoma
- Trial name
- RADCHOP (NCT01198665)
- Testing
- RAD001 (Everolimus)
- Where
- 5 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- Samsung Medical Center
Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
The purpose of this study is to determine whether intravenous Bortezomib combined with oral Panobinostat (LBH589) are effective in treating adult patients with relapsed/refractory peripheral T-cell lymphoma or NK/T-cell lymphoma…
- Conditions
- Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma, Extranodal NK/T-cell Lymphoma Nasal Type, Enteropathy- Type T-cell Lymphoma
- Trial name
- NCT00901147
- Testing
- panobinostat and bortezomib
- Where
- 5 sites in Malaysia, Singapore and 1 more
- Volunteers
- 25 people
- Sponsor
- Singapore General Hospital